235 related articles for article (PubMed ID: 22196061)
1. A phase II study of irinotecan in combination with cisplatin as second-line chemotherapy in patients with metastatic or locally advanced gastric cancer.
Shen WC; Yang TS; Hsu HC; Chen JS
Chang Gung Med J; 2011; 34(6):590-8. PubMed ID: 22196061
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
Park KW; Ahn JS; Park YS; Lee J; Kang JH; Park JO; Lim HY; Im YH; Kang WK; Park K; Lee SI
Cancer Chemother Pharmacol; 2007 Jan; 59(1):17-21. PubMed ID: 16721549
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of sequential treatment with S-1 and cisplatin for metastatic gastric cancer.
Baba E; Esaki T; Ariyama H; Mitsugi K; Morikita T; Fujishima H; Kusaba H; Nakano S; Akashi K
Cancer Chemother Pharmacol; 2011 Sep; 68(3):611-7. PubMed ID: 21116623
[TBL] [Abstract][Full Text] [Related]
4. Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes.
Park SH; Choi EY; Bang SM; Cho EK; Lee JH; Shin DB; Ki Lee W; Chung M
Anticancer Drugs; 2005 Jul; 16(6):621-5. PubMed ID: 15930889
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ
Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.
Ilson DH
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):22-5. PubMed ID: 15685830
[TBL] [Abstract][Full Text] [Related]
7. Phase 1/11 study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer.
Koizumi W; Kurihara M; Satoh A; Takiuchi H; Tanabe S; Shimada K; Iwasaki R; Saigenji K
Anticancer Res; 2005; 25(2B):1257-62. PubMed ID: 15865075
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma.
Ajani JA; Baker J; Pisters PW; Ho L; Mansfield PF; Feig BW; Charnsangavej C
Oncology (Williston Park); 2002 May; 16(5 Suppl 5):16-8. PubMed ID: 12109800
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma.
Scott LC; Yao JC; Benson AB; Thomas AL; Falk S; Mena RR; Picus J; Wright J; Mulcahy MF; Ajani JA; Evans TR
Cancer Chemother Pharmacol; 2009 Jan; 63(2):363-70. PubMed ID: 18398613
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer.
Ueda S; Hironaka S; Boku N; Fukutomi A; Yoshino T; Onozawa Y
Gastric Cancer; 2006; 9(3):203-7. PubMed ID: 16952039
[TBL] [Abstract][Full Text] [Related]
11. Feasibility study of biweekly CPT-11 plus CDDP for S-1- and paclitaxel-refractory, metastatic gastric cancer.
Yoshida T; Yoshikawa T; Tsuburaya A; Kobayashi O; Hasegawa S; Osaragi T; Sairenji M
Anticancer Res; 2006; 26(2B):1595-8. PubMed ID: 16619577
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
[TBL] [Abstract][Full Text] [Related]
13. Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial).
Higuchi K; Tanabe S; Shimada K; Hosaka H; Sasaki E; Nakayama N; Takeda Y; Moriwaki T; Amagai K; Sekikawa T; Sakuyama T; Kanda T; Sasaki T; Azuma M; Takahashi F; Takeuchi M; Koizumi W;
Eur J Cancer; 2014 May; 50(8):1437-45. PubMed ID: 24560487
[TBL] [Abstract][Full Text] [Related]
14. Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study.
Baek JH; Kim JG; Sohn SK; Kim DH; Lee KB; Song HS; Kwon KY; Do YR; Ryoo HM; Bae SH; Park KU; Kim MK; Lee KH; Hyun MS; Chung HY; Yu W
J Korean Med Sci; 2005 Dec; 20(6):966-70. PubMed ID: 16361806
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
Sato Y; Takayama T; Sagawa T; Takahashi Y; Ohnuma H; Okubo S; Shintani N; Tanaka S; Kida M; Sato Y; Ohta H; Miyanishi K; Sato T; Takimoto R; Kobune M; Yamaguchi K; Hirata K; Niitsu Y; Kato J
Cancer Chemother Pharmacol; 2010 Sep; 66(4):721-8. PubMed ID: 20041328
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
[TBL] [Abstract][Full Text] [Related]
17. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT).
Wöll E; Greil R; Eisterer W; Bechter O; Fridrik MA; Grünberger B; Zabernigg A; Mayrbäurl B; Russ G; Dlaska M; Obrist P; Thaler J
Anticancer Res; 2011 Dec; 31(12):4439-43. PubMed ID: 22199312
[TBL] [Abstract][Full Text] [Related]
19. Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer.
Kucukzeybek Y; Dirican A; Erten C; Somali I; Can A; Demir L; Bayoglu IV; Akyol M; Medeni M; Tarhan MO
Asian Pac J Cancer Prev; 2012; 13(6):2771-4. PubMed ID: 22938457
[TBL] [Abstract][Full Text] [Related]
20. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
